ADA Releases Recommendations on Managing the Care of Patients on Osteoporosis Drugs
Date: November 03, 2011
The American Dental Association (ADA) Council on Scientific Affairs last week released its recommendations for patients receiving antiresorptive therapy for the prevention and treatment of osteoporosis. In recent years, there has been concern of a possible association between osteonecrosis of the jaw and osteoporosis drugs which resulted in some dentists refusing treatment for individuals on bisphosphonates or other antiresorptive agents for the treatment of osteoporosis. The ADA recommendations conclude that “the highest reliable estimate of antiresorptive agent-induced osteonecrosis of the jaw (ARONJ) prevalence is approximately 0.10 percent. Osteoporosis is responsible for considerable morbidity and mortality. Therefore, the benefit provided by antiresorptive therapy outweighs the low risk of developing ONJ.” The full report is available on the Journal of the American Dental Association (JADA) website. A summary of the ADA Recommendations is featured in this week's ASBMR Scientific Web Editor blog titled: "Risks and the Use of Antiresorptive Therapies."